Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Mavrostobart (PT199)
DRUG: Tislelizumab
DRUG: Gemcitabine + nab-Paclitaxel
DRUG: Docetaxel
DRUG: Pemetrexed
DRUG: Gemcitabine
DRUG: Carboplatin + Pemetrexed
DRUG: Pembrolizumab + Carboplatin + Pemetrexed

Sponsor

Phanes Therapeutics

Collaborators

[object Object]